Subsequently, we discovered that across all tumor cell subpopulations, the C2 MKI67+ TCs were mostly present in tumor stages II, III, and IV, called for their elevated expression of MKI67. MKI67 has been identified as a potential diagnostic and prognostic biomarker for mismatch repair. The gene discussed is MKI67; the disease is neoplasm.